Biotech has been one of the worst-performing industry groups this cycle. Investors have got used to it as these stocks have been dead money for much of the past decade.
Stop losses. Profit targets. They’re there for a reason. They say, “This is as far as I’m willing to go.” They define my comfort zone — both for risk and for reward.
Every day, we sift through the filings to spot where the real conviction lies – cutting through the noise to highlight the most meaningful insider moves.
